The exact prevalence of epileptic seizures in patients with multiple sclerosis (MS) is still a matter of some controversy. In a population-based, unselected group of 423 patients with MS we identified 17 (4.02%) with epileptic seizures. The mean age at onset of MS was 25.2 years and at onset of epilepsy 32.6 years. A prevalence of 'active epilepsy', i.e. seizures within the last 5 years, was estimated to 3.2%. The prevalence of epilepsy in our MS population is much higher than should be expected when compared to lifetime prevalence of epilepsy in corresponding age groups. The occurrence of convulsive status epilepticus is also higher than expected, and suggests a rather serious prognosis. Thus, drug treatment should be considered after the first epileptic seizure.
INTRODUCTION
Multiple sclerosis (MS) is a demyelinating disease, with symptoms due to impaired central impulse propagation. Clinicians often assume a low seizure frequency in MS patients.
Considerable variations in seizure occurrence in MS patients are reported, generally in the order of OS'-4.5%'-'.
A recent study showed an overall seizure prevalence of 1.7% in MS, with 2.3% in cases with definite MS*. Thus, the prevalence of seizures in MS is still uncertain, and EEG studies have even suggested 'epileptic' abnormalities in up to 10%9. Furthermore, knowledge is rather sparse concerning severity and prognosis of epilepsy in MS patients.
Having diagnosed epilepsy in four MS patients within 2 years, we examined the occurrence, characteristics and prognosis of seizures in our MS population. The only Department of Neurology in Hordaland county is in Bergen. Thus, all patients with MS and/or epilepsy are likely to be referred to our department.
METHODS
We retrospectively evaluated the occurrence of epileptic seizures and epilepsy in our population of 423 patients (254 female and 169 male) with onset and diagnosis of MS between 1958 and 1988, in the county of Hordaland". For seizure classification, the ILAE terminology of 1981 was used (Epilepsia 1981; 22: 489-501).
RESULTS
Of 423 MS patients, 17 had epileptic seizures (4.02%). Of these, 16 qualified for the diagnosis of epilepsy (3.8%) (Table l) , and one additional patient had an ascertained epileptic seizure and repeated EEG registrations showing epileptic or epileptiform EEG activity (Table 2) . Their mean age at onset of MS was 25.2 f 5.6 (sd) years, and at onset of epileptic seizures 32.6 f 7.9 years. Of these patients, six were males (mean age at & M. Grenning seizure onset: 35.6 years) and 11 were females (mean age at seizure onset: 42.6 years). On January 1st 1992 343 patients were alive. Of these, 14 (4.08%) had epilepsy, and 11 had had known seizures within the last 5 years (3.2%).
According to the criteria of MacAlpine", 16 patients had definite and one probable MS. Fourteen patients had 'primary remitting relapsing' (PRR), and three had 'primary chronic progressive' (PCP) MS" ( Table 1 ). Of the Patient Sex MS diagnosis was established, and 10 years after the first ascertained epileptic seizure. In this patient, investigations, including cerebral angiography, did not reveal signs of tumour at the time of seizure onset.
DISCUSSION
All patients had focal epileptic seizures. The diagnosis was based on focal EEG findings (n = 7) and/or a good description of the seizure development (n = 11) ( Table 2 ). Five patients had complex partial seizures (CPS) with or without a secondary generalization, suggesting, most likely, a lateral or mesial temporal lobe focus. One patient had simple partial seizures (SPS) of a likely parietal origin, and 11 patients had likely cortical or immediate subcortical foci with secondary generalized tonic-clonic convulsions (sGTC).
For some time 16 patients used antiepileptic drugs (AED). Of these, 11 used carbamazepine (400-800mg daily), four used phenytoin (3-400 mg daily) and one used phenobarbital (100 mg). At the time of evaluation, 11 patients still used AED, and three were without. Three patients had died, and had been using AED at time of death (Patients 05, 14 and 15).
The present study supports previous investigations suggesting a higher occurrence of epileptic seizures in MS patients than in the general population 1,2*7.8. Variation in occurrence rates between 0.45%13 and 10.8%9 of epilepsy in MS hardly reflects intergroup, for instance genetic, differences alone. Even if occurrence rates are reduced to between 0.5% and 4.5%12 they point to methodological differences such as patient selection, differences of terminology, i.e. diagnostic criteria of MS, definition of epilepsy and lack of differentiation between event-related seizures and seizures in epilepsy. Our study is based on the total population of MS patients in the county of Hordaland from 1958 to 1988l'. The diagnosis of both MS and epileptic seizures or epilepsy are based on thorough examination of the patients at the Department of Neurology, Haukeland Hospital.
Four patients had status epilepticus (SE) (23.5%) ( Table 3 '7,14 , occuring in addition to other epileptic seizures in this patient. In general, all epileptic seizures were readily distinguishable from other non-epileptic 'paroxysmal' events "-l'. In all our patients a focal epilepsy was diagnosed and the MS considered a likely cause of their epilepsy. However, in four patients other causes for seizures were considered, but were less likely than the MS.
The female-to-male ratio of 1:8 could suggest a preponderance of females among epileptic MS patient$. However, this is most likely simply to reflect the general MS poulation'. In accordance with other authors, we could not find any clear correlation between epilepic seizures and the severity or excacaberbation of MS. Intercurrent infections may, in some patients, contribute to isolated seizures, but the exact prevalence of such a contributing factor is uncertain.
Coincidental association between epilepsy and MS may occur'. This is especially the case when onset of epilepsy precedes symptoms of MS. In three or four (Table 1) Interestingly, a recent study revealed higher prevalence of epilepsy in patients with definite (2.3%) vs. probable (0.79%) MS8. The mean age at onset of epiletpic seizures in our patients was 32.6 years, which is in accordance with other authors'*", and at an age with low age-specific prevalence for epilepsy'2. This fact may further support the notion of MS as an etiological factor responsible for symptomatic epilepsy in some patients.
The mechanism of epileptogenesis is not clear, but demyelinated lesions may act as irritative foci and MS plaques are found adjacent to, and extending into, the cerebral cortex in general", and in a few autopsied patients with MS and epilepsy . 'B Ectopic impulse generation, edema and other inflammatory reactions may contribute to abnormal nerve cell activity.
As, in general, seizures did not correlate with signs of activity of MS in our patients, this argues against an important role of inflammation in seizure initiation.
Concerning prognosis, Mtiller suggested in 1949 that in MS 'the prognosis of epilepsy is better than otherwise is the case"'. Similarly, only seven of the 13 patients in Drake & Macrea's study 'required' anti-convulsant therapy2. Different authors suggest that epilepsy in MS patients may fall into two major groups.2,4*'* In one, the seizures are chronic but infrequent and unrelated to activity of MS. In the other group, seizures are associated with rapidly increasing disability and are often difficult to control'. In a possible third group, several seizures occur during acute relapse, with no recurrent sporadic seizures7*'5*'6. In the latter group it has been suggested that the diagnosis 'event-related seizures' might be more adequate than epilepsy"-". Status epilepticus (SE) in four out of 17 patients suggests a higher risk of SE in MS patients than the 2-10% risk suggested for a general population of epilepsy patients, depending on age and type of epilepsy". SE in MS seems to be 'rare' in some populations", but does OCCU?'*~, i.e. in two of 13 cases2, and may be a terminal event in disabled patients18*22. Our findings support the notion that SE is a serious threat to MS patients with epilepsy, and that epilepsy should be considered an important risk factor in MS patients. The risk of new seizures, SE, and a high prevalence of 'active epilepsy' suggests a need for early use of AED and close follow-up of patients with MS and epileptic seizures.
